Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 chronic lung disorders. They are characterized by inflammation and scarring of the lung interstitium, leading to progressive dyspnea and impaired gas exchange. This article provides a comprehensive overview of ILDs, focusing on etiology, clinical features, diagnostic approaches, and treatment strategies.
ILDs can be classified based on their etiology into idiopathic, occupational, drug-induced, and those associated with systemic diseases. The most common form is idiopathic pulmonary fibrosis (IPF), the cause of which remains unknown. Occupational and drug-induced ILDs are caused by exposure to harmful substances or certain medications respectively, while systemic diseases like rheumatoid arthritis or scleroderma may also involve the lung interstitium.
Patients with ILDs typically present with chronic, progressive dyspnea and non-productive cough. Physical examination may reveal bibasilar inspiratory crackles and finger clubbing. Advanced stages may manifest with signs of right heart failure due to pulmonary hypertension.
High-resolution computed tomography (HRCT) is the cornerstone of ILD diagnosis, showing characteristic patterns like honeycombing in IPF. Pulmonary function tests reveal a restrictive pattern with reduced diffusion capacity. In certain cases, a lung biopsy may be necessary to confirm the diagnosis.
Treatment of ILDs is largely dependent on the underlying cause. For idiopathic forms, antifibrotic agents like pirfenidone and nintedanib have shown efficacy in slowing disease progression. Corticosteroids and immunosuppressants are used in ILDs associated with systemic diseases. Lung transplantation remains the only curative option for advanced disease.
ILDs are complex disorders requiring a comprehensive diagnostic approach and individualized management strategies. Continued research into their pathogenesis and treatment is crucial for improving patient outcomes. It is important for healthcare professionals to stay updated on the latest advancements in this field.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation